Arrowhead Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock and has a $80.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Patrick Trucchio has given his Buy rating due to a combination of factors, primarily focusing on the strategic advancements and financial benefits stemming from Arrowhead Pharmaceuticals’ collaboration with Sarepta Therapeutics. The RNAi pipeline of Arrowhead is progressing towards commercial maturity, which is further bolstered by the partnership with Sarepta. This collaboration is seen as mutually beneficial, with Sarepta prioritizing the development and commercialization of the small interfering RNA (siRNA) programs licensed from Arrowhead.
The financial terms of the partnership are robust, providing Arrowhead with significant upfront cash payments and equity investments. Additionally, Arrowhead is positioned to receive substantial milestone payments as the programs advance. The partnership not only strengthens Arrowhead’s financial position but also supports its strategic goal of transitioning to cash flow-positive operations by 2030. The collaboration is valued at $18 per share, contributing to the reiterated Buy rating and the $80 price target for Arrowhead’s stock.